Patrick J. Scannon
31Patents
11h-index
26Co-inventors
75Inventor score
Filing activity: Oct 28, 1983 → Sep 8, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4925922A | Potentiation of cytotoxic conjugates | Emerging Cross-Sectional Technologies | 103 | Expired |
| US4916213A | Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof | Emerging Cross-Sectional Technologies | 86 | Expired |
| US4473496A | Intramolecularly crosslinked hemoglobin | Emerging Cross-Sectional Technologies | 59 | Expired |
| US4590071A | Human melanoma specific immunotoxins | Human Necessities | 51 | Expired |
| US8584349B2 | Flexible manufacturing system | Emerging Cross-Sectional Technologies | 30 | Active |
| US5686414A | Methods of treating conditions associated with corneal transplantation | Human Necessities | 26 | Expired |
| US4664913A | Method for treating plasma for transfusion | Human Necessities | 25 | Expired |
| US5627153A | Anti-fungal methods and materials | Human Necessities | 22 | Expired |
| US5643875A | Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products | Emerging Cross-Sectional Technologies | 19 | Expired |
| US10294658B2 | Flexible manufacturing system | Emerging Cross-Sectional Technologies | 16 | Active |
| US7695718B2 | Methods for the treatment of IL-1β related diseases | Chemistry; Metallurgy | 13 | Active |
| US5756464A | Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma | Emerging Cross-Sectional Technologies | 11 | Expired |
| US5753620A | Human therapeutic uses of BPI protein products | Emerging Cross-Sectional Technologies | 10 | Expired |
| US5888977A | Therapeutic uses of BPI protein products for human meningococcemia | Emerging Cross-Sectional Technologies | 4 | Expired |
| US5952302A | Human therapeutic uses of BPI protein products | Emerging Cross-Sectional Technologies | 4 | Expired |
| US8377429B2 | Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof | Chemistry; Metallurgy | 3 | Active |
| US5990086A | Therapeutic uses of BPI protein products for human meningococcemia | Emerging Cross-Sectional Technologies | 3 | Expired |
| US8101166B2 | Methods for the treatment of IL-1β related diseases | Chemistry; Metallurgy | 2 | Active |
| US5945399A | Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma | Emerging Cross-Sectional Technologies | 2 | Expired |
| US6242418A | Therapeutic uses of BPI protein products for human meningococcemia | Emerging Cross-Sectional Technologies | 1 | Expired |
| US6509317B1 | Method of treating chronic cardiac disease | Human Necessities | 1 | Expired |
| US6191112A | Human therapeutic uses of BPI protein products | Emerging Cross-Sectional Technologies | 1 | Expired |
| US10611832B2 | Cardiovascular related uses of IL-1β antibodies and binding fragments thereof | Human Necessities | 0 | Active |
| US10106974B2 | Flexible manufacturing system | Emerging Cross-Sectional Technologies | 0 | Active |
| US12275974B2 | Synthetic enzyme complexes for in vitro rubber production | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.